Aequus Pharmaceuticals Inc
- LAST PRICE0.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0050/ 3,870
- Ask / Lots0.0150/ 676
- Open / Previous Close--- / 0.0100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AQS |
|---|---|---|
| 12:51 ET | 37000 | 0.01 |
Nov 12, 2024
Aequus Provides Update and Reports Third Quarter 2024 Financial Highlights., from 5:26PM ET on Tuesday Nov 12, 2024 by Dow Jones
5:26PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
Aequus Provides Update and Reports Third Quarter 2024 Financial Highlights, from 9:12PM ET on Friday Nov 08, 2024 by Dow Jones
9:12PM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aequus Pharmaceuticals Inc | 1.3M | -0.5x | --- |
Manitex Capital Inc | 1.7M | -3.7x | +16.92% |
Lucy Scientific Discovery Inc | 880.1K | -2.3x | --- |
Lumiera Health Inc | 866.0K | -0.4x | --- |
Medcolcanna Organics Inc | 594.6K | -0.1x | --- |
Jolt Health Inc | 636.5K | -0.6x | --- |
Company Information
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.
Contact Information
- Headquarters
- Suite 2820, 200 Granville StreetVANCOUVER, BC, Canada V6C 1S4
- Phone
- 604-336-7906
- Fax
- 604-336-7906
Executives
- Chairman of the Board, President, Chief Executive Officer
- Douglas Janzen
- Chief Financial Officer, Corporate Secretary
- Ann Fehr
- Chief Commercial Officer
- Grant Larsen
- Director
- Christopher Clark
- Independent Director
- Marc Lustig
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3M |
|---|---|
Revenue (TTM) | $413.2K |
Shares Outstanding | 132.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.05 |
EPS | $-0.02 |
Book Value | $-0.03 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -657.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
